CANY
PBYI icon

Caxton Associates (New York)’s Puma Biotechnology PBYI Stock Holding History

Caxton Associates (New York)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,247
Closed -$57.4K – 562
2023
Q2 		$57.4K Sell
16,247
-8,363
-34% -$26.1K 0.01% 469
2023
Q1 		$76K Buy
+24,610
New +$92.8K 0.01% 470

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caxton Associates (New York)'s PBYI Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Puma Biotechnology (PBYI) in Q3 2023, closing a stake of 16,247 shares — an estimated $57.4K sold.

Caxton Associates (New York) first reported a position in PBYI in Q1 2023 and held it in 2 quarters. The position peaked at $76K in Q1 2023. 69 funds tracked by Wall St. Rank hold PBYI as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Puma Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 16,247 Puma Biotechnology shares in Q3 2023, an estimated $57.4K.
  • Caxton Associates (New York) first reported a position in Puma Biotechnology in Q1 2023 and held it in 2 quarters.
  • Caxton Associates (New York)'s Puma Biotechnology position peaked at $76K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.